In this context, selective COX-2 inhibitors, such as coxibs, may represent a better choice to control cancer-related pain, as they have been significantly associated with reduced mortality and fewer emergency department visits across various cancer types, including breast, colorectal, melanoma, pancreatic, liver, biliary tract, lymphohematopoietic, lung, and prostate cancers. The gene discussed is PTGS2; the disease is melanoma.